🇪🇺 BIIB041 (Fampridine-SR) in European Union

EMA authorised BIIB041 (Fampridine-SR) on 20 July 2011

Marketing authorisation

EMA — authorised 20 July 2011

  • Application: EMEA/H/C/002097
  • Marketing authorisation holder: Merz Therapeutics GmbH
  • Local brand name: Fampyra
  • Indication: Fampyra is indicated for the improvement of walking in adult patients with multiple sclerosis with walking disability (Expanded Disability Status Scale 4-7).
  • Status: approved

Read official source →

Other Neurology approved in European Union

Frequently asked questions

Is BIIB041 (Fampridine-SR) approved in European Union?

Yes. EMA authorised it on 20 July 2011.

Who is the marketing authorisation holder for BIIB041 (Fampridine-SR) in European Union?

Merz Therapeutics GmbH holds the EU marketing authorisation.